Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report - 20/08/22
, G.M.C. Masclee a, A.A. van der Eijk b, C.J. van der Woude a, R.A. de Man a, A.C. de Vries aAbstract |
We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.
Il testo completo di questo articolo è disponibile in PDF.Key words : Hepatitis E, Vedolizumab, IBD, Crohn's disease
Abbreviations : ALT, AMA, ANA, AP, ASMA, AST, CD, CRP, GGT, HEV, IBD, LDH, N, PCR, PT-INR, RNA, TNF-α, UC, WBC
Mappa
Vol 46 - N° 7
Articolo 101948- agosto 2022 Ritorno al numero
Articolo precedente
- Chaperonin-containing tailless complex polypeptide 1 subunit 6A links with aggravating tumor features and disease-free survival in surgical gastric cancer patients: A long-term follow-up study
- Tingbang He, Deguo Yu, Zhenfeng Wang, Changcai Guo, Yong Chang, Dapeng Wang
- Ciliated hepatic foregut cyst: An uncommon cystic liver lesion
- Emanuel Dias, Hélder Cardoso, João Pacheco, Joanne Lopes, Guilherme Macedo
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?